NeoGenomics (NEO) CEO Chris Smith to retire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
NeoGenomics Announces Chief Executive Officer Succession
January 10, 2025 7:05 AM ESTChris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO
Company reaffirms Fiscal 2024 financial guidance
FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ: NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.
Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time and... More



